Tests vitamin D3 with lenalidomide in people with multiple myeloma
Compares vitamin D3 maintenance with no vitamin D after stem cell transplant in myeloma.
Key facts
- Who runs it
- Amany Keruakous, MD, MS.
- Where
- Augusta, United StatesSee the site
- Trial code
- Registry title
- VitD3 Supplementation in Patients With Multiple Myeloma
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 100 people, planned
- Started
- 1 Dec 2024
- Expected to end
- May 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Lenalidomide
- Maintenance Vitamin D
- No maintenance Vitamin D
- Record updated
- 8 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with symptomatic multiple myeloma who are ready for an autologous stem cell transplant and will take lenalidomide afterwards, with or without vitamin D.
- Age
- 18 years or older.
- Sex
- Women and men can join.
- Disease stage
- Symptomatic multiple myeloma with measurable disease at diagnosis, which needed treatment before the transplant. Smoldering myeloma does not count until it has become symptomatic.
- Earlier treatment
- Must have needed systemic induction therapy before the transplant. Cannot have had a prior allograft, a prior organ transplant needing immunosuppressive therapy, or a previous autologous transplant.
- Biomarker or test result
- Measurable M protein in the serum (≥ 0.5g/dL) or urine (≥ 200 mg/24h), or serum free light chain of ≥ 10 mg/dL (≥ 100 mg/L), at the time of diagnosis.
Main reasons for not taking part
- Amyloidosis affecting any organ
- Progressive disease at any time before registration
- Intolerance to or refractory disease with lenalidomide
- Hepatitis B or hepatitis C positive blood test
- Serum calcium level above 10.3 mg/dL
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Patients must be ≥ 18 years of age at time of registration to Step 1
- Patients must have history and physical exam within 28 days prior to registration
- Patients must have Zubrod/ECOG Performance Status ≤ 2
- Patients must have had a confirmed diagnosis of symptomatic MM (See Section 4.1) with measurable disease at the time of myeloma diagnosis that required systemic induction therapy prior to ASCT. Measurable disease is defined as measurable M protein in the serum (≥ 0.5g/dL) or urine (≥ 200 mg/24h) or serum free light chain assay (defined as ≥ 10 mg/dL [≥ 100 mg/L] on involved light chain) at the time of diagnosis. Patients with smoldering myeloma are not eligible until they have progressed to symptomatic myeloma
- Patients must be willing and able to take DVT prophylaxis (aspirin, low molecular weight heparin, warfarin, or equivalent oral anticoagulation) and comply with lenalidomide REMS program requirements
- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to registration. FCBP must agree to have a second pregnancy test within 24 hours prior to starting lenalidomide. Further, FCBP must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide. FCBP must also agree to ongoing pregnancy testing and must agree to not become pregnant for at least 3 months after the last dose of study treatment. A FCBP is a female who: 1) has achieved menarche (first menstrual cycle) at some point, 2) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months).Men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy, during the study treatment and for 3 months after the last dose of study treatment
- Patients must have evidence of adequate renal function, as defined by (1) creatinine clearance (CrCl) ≥ 10 mL/min., as measured by a 24-hour urine collection, or estimated by the Cockcroft and Gault formula. Values must be obtained within 28 days prior to registration. Estimated creatinine clearance = (140 - age) x wt (kg) x 0.85 (if female) 72 x creatinine (mg/dl)
- Patients must have adequate hepatic function defined by the following within 28 days prior to registration: Total bilirubin ≤ 1.5 x IULN (institutional upper limit of the norm) and AST and ALT ≤ 3.0 x IULN
- Patients must be acceptable for transplant per institutional guidelines:
- Patient's with human immunodeficiency virus (HIV) are eligible providing they are on effective antiretroviral therapy and have undetectable viral load at their most previous viral load test and within 6 months prior to registration
- Patients must be able to take and swallow oral medication (capsules) whole
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
Who cannot take part
- Progressive disease at any time prior to registration
- Prior allograft, prior organ transplant requiring immunosuppressive therapy, or have already received a previous autologous transplantation (e.g., requiring second ASCT at time of screening)
- Received any investigational agents within 14 days prior to registration
- Patients that have received any investigational agents within 14 days prior to registration
- Prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years
- Seropositive for Hepatitis B
- Seropositive for Hepatitis C
- Any known impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection). h known allergies to any of the study drugs
- Hypercalcemia (serum calcium level > 10.3 mg/dL) (institutional upper limit of the norm) at time of study entry
- Any organ involvement by amyloidosis or evidence of amyloidosis related organ dysfunction
- Intolerance to the starting dose of lenalidomide (10 mg)
- Patients refractory to lenalidomide
Where in United States
- Georgia Cancer Center at Augusta UniversityAugusta, United StatesContact: Kelly Jenkins, MSN, RNTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate post-transplant immune reconstitution and lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple myeloma in two treatment arms. One arm will receive Maintenance Vitamin D and the other arm will receive no maintenance Vitamin D prior to ASCT. Post ASCT arm 1 will have lenalidomide and maintenance VitD, and arm 2 will receive lenalidomide and no maintenance VitD. This clinical trial will also evaluate the overall response rate and survival for both treatment arms.
The 2 groups in the trial
- Maintenance Vitamin DTreatment being tested
In this arm, patients will receive maintenance Vitamin D3 prior to autologous transplantation (ASCT). Within 120 days after ASCT the following will be assessed: vitamin D level, Overall Response Rate (ORR) and Measurable Residual Disease (MRD). Then patients will receive lenalidomide and continuation of maintenance Vitamin D.
Treatment: Lenalidomide and Maintenance Vitamin D
- No Maintenance Vitamin DExisting treatment, for comparison
In this arm, patients will receive no maintenance vitamin D prior to ASCT. Within 120 days after ASCT the following will be assessed: vitamin D level, ORR, and MRD. Then patients will receive the standard lenalidomide dose along with no maintenance vitamin D.
Treatment: Lenalidomide and No maintenance Vitamin D
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- EVALUATION OF CHOLECALCIFEROL (VitD3) MAINTENANCE SUPPLEMENTATION IN PATIENTS WITH MULTIPLE MYELOMA (MM) UNDERGOING TRANSPLANTATION AND IN COMBINATION WITH LENALIDOMIDE MAINTENANCE
- Plain-language title
- Tests vitamin D3 with lenalidomide in people with multiple myelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 April 2025